• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

恶性疟原虫对哌喹和咯萘啶的体外敏感性呈多正态分布。

Multinormal in vitro distribution of Plasmodium falciparum susceptibility to piperaquine and pyronaridine.

作者信息

Pascual Aurélie, Madamet Marilyn, Briolant Sébastien, Gaillard Tiphaine, Amalvict Rémy, Benoit Nicolas, Travers Dominique, Pradines Bruno

出版信息

Malar J. 2015 Feb 5;14:49. doi: 10.1186/s12936-015-0586-6.

DOI:10.1186/s12936-015-0586-6
PMID:25848972
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4323025/
Abstract

BACKGROUND

In 2002, the World Health Organization recommended that artemisinin-based combination therapy (ACT) be used to treat uncomplicated malaria. Dihydroartemisinin-piperaquine and artesunate-pyronaridine are two of these new combinations. The aim of the present work was to assess the distribution of the in vitro values of pyronaridine (PND) and piperaquine (PPQ) and to define a cut-off for reduced susceptibility for the two anti-malarial drugs.

METHODS

The distribution and range of the 50% inhibitory concentration values (IC₅₀) of PND and PPQ were determined for 313 isolates obtained between 2008 and 2012 from patients hospitalized in France for imported malaria. The statistical Bayesian analysis was designed to answer the specific question of whether Plasmodium falciparum has different phenotypes of susceptibility to PND and PPQ.

RESULTS

The PND IC₅₀ values ranged from 0.6 to 84.6 nM, with a geometric mean of 21.1 ± 16.0 nM (standard deviation). These values were classified into three components. The PPQ IC₅₀ values ranged from 9.8 to 217.3 nM, and the geometric mean was 58.0 ± 34.5 nM. All 313 PPQ values were classified into four components. Isolates with IC₅₀ values greater than 60 nM or four-fold greater than 3D7 IC₅₀ are considered isolates that have reduced susceptibility to PND and those with IC₅₀ values greater than 135 nM or 2.3-fold greater than 3D7 IC₅₀ are considered isolates that have reduced susceptibility to PPQ.

CONCLUSION

The existence of at least three phenotypes for PND and four phenotypes for PPQ was demonstrated. Based on the cut-off values, 18 isolates (5.8%) and 13 isolates (4.2%) demonstrated reduced susceptibility to PND and PPQ, respectively.

摘要

背景

2002年,世界卫生组织建议使用以青蒿素为基础的联合疗法(ACT)治疗非复杂性疟疾。双氢青蒿素哌喹和青蒿琥酯咯萘啶是其中两种新的联合用药。本研究的目的是评估咯萘啶(PND)和哌喹(PPQ)的体外值分布,并确定这两种抗疟药物敏感性降低的临界值。

方法

测定了2008年至2012年间从法国因输入性疟疾住院的患者中分离出的313株疟原虫对PND和PPQ的50%抑制浓度值(IC₅₀)的分布和范围。统计贝叶斯分析旨在回答恶性疟原虫对PND和PPQ是否具有不同敏感性表型这一具体问题。

结果

PND的IC₅₀值范围为0.6至84.6 nM,几何平均值为21.1±16.0 nM(标准差)。这些值分为三个组分。PPQ的IC₅₀值范围为9.8至217.3 nM,几何平均值为58.0±34.5 nM。所有313个PPQ值分为四个组分。IC₅₀值大于60 nM或比3D7的IC₅₀值大四倍的分离株被认为是对PND敏感性降低的分离株,而IC₅₀值大于135 nM或比3D7的IC₅₀值大2.3倍的分离株被认为是对PPQ敏感性降低的分离株。

结论

证实了PND至少存在三种表型,PPQ存在四种表型。根据临界值,分别有18株(5.8%)和13株(4.2%)分离株对PND和PPQ的敏感性降低。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6806/4323025/b1bdef8e509a/12936_2015_586_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6806/4323025/dad6078e340e/12936_2015_586_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6806/4323025/7c15da2b5a5a/12936_2015_586_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6806/4323025/b1bdef8e509a/12936_2015_586_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6806/4323025/dad6078e340e/12936_2015_586_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6806/4323025/7c15da2b5a5a/12936_2015_586_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6806/4323025/b1bdef8e509a/12936_2015_586_Fig3_HTML.jpg

相似文献

1
Multinormal in vitro distribution of Plasmodium falciparum susceptibility to piperaquine and pyronaridine.恶性疟原虫对哌喹和咯萘啶的体外敏感性呈多正态分布。
Malar J. 2015 Feb 5;14:49. doi: 10.1186/s12936-015-0586-6.
2
Ex vivo activity of the ACT new components pyronaridine and piperaquine in comparison with conventional ACT drugs against isolates of Plasmodium falciparum.体外试验中 ACT 新药成分哌喹和氨酚喹啉与传统 ACT 药物对恶性疟原虫分离株的活性比较。
Malar J. 2012 Feb 14;11:45. doi: 10.1186/1475-2875-11-45.
3
Plasmodium falciparum susceptibility to standard and potential anti-malarial drugs in Dakar, Senegal, during the 2013-2014 malaria season.2013 - 2014年疟疾季节期间,塞内加尔达喀尔恶性疟原虫对标准和潜在抗疟药物的敏感性
Malar J. 2015 Feb 6;14:60. doi: 10.1186/s12936-015-0589-3.
4
Temporal changes in Plasmodium falciparum anti-malarial drug sensitivity in vitro and resistance-associated genetic mutations in isolates from Papua New Guinea.巴布亚新几内亚恶性疟原虫体外抗疟药物敏感性及分离株中耐药相关基因突变的时间变化。
Malar J. 2015 Jan 28;14:37. doi: 10.1186/s12936-015-0560-3.
5
[In vitro sensitivity of Plasmodium falciparum isolates from China-Myanmar border region to chloroquine, piperaquine and pyronaridine].[中国-缅甸边境地区恶性疟原虫分离株对氯喹、哌喹和咯萘啶的体外敏感性]
Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi. 2012 Feb 29;30(1):41-4.
6
[In vitro sensitivity of Plasmodium falciparum to chloroquine, piperaquine, pyronaridine and artesunate in Yuxi prefecture of Yunnan province].云南省玉溪市恶性疟原虫对氯喹、哌喹、咯萘啶和青蒿琥酯的体外敏感性
Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi. 1998;16(6):460-2.
7
In vitro susceptibility of Plasmodium falciparum isolates from Abidjan, Côte d'Ivoire, to artemisinin, chloroquine, dihydroartemisinin and pyronaridine.来自科特迪瓦阿比让的恶性疟原虫分离株对青蒿素、氯喹、双氢青蒿素和咯萘啶的体外敏感性。
Tanzan J Health Res. 2010 Jan;12(1):73-9. doi: 10.4314/thrb.v12i1.56364.
8
Piperaquine resistant Cambodian Plasmodium falciparum clinical isolates: in vitro genotypic and phenotypic characterization.哌喹耐药柬埔寨疟原虫临床分离株的体外基因和表型特征。
Malar J. 2020 Jul 25;19(1):269. doi: 10.1186/s12936-020-03339-w.
9
Multinormal in vitro distribution model suitable for the distribution of Plasmodium falciparum chemosusceptibility to doxycycline.适用于恶性疟原虫对多西环素化学敏感性分布的多正态体外分布模型。
Antimicrob Agents Chemother. 2009 Feb;53(2):688-95. doi: 10.1128/AAC.00546-08. Epub 2008 Dec 1.
10
In Vitro Sensitivity of Pyronaridine in Thai Isolates of .泰国分离株.. 吡喹酮的体外敏感性
Am J Trop Med Hyg. 2018 Jan;98(1):51-56. doi: 10.4269/ajtmh.17-0286. Epub 2018 Jan 1.

引用本文的文献

1
Assessment of ex vivo antimalarial drug efficacy in African Plasmodium falciparum parasite isolates, 2016-2023: a genotype-phenotype association study.2016 - 2023年非洲恶性疟原虫分离株离体抗疟药物疗效评估:一项基因型 - 表型关联研究
EBioMedicine. 2025 Jul 9;118:105835. doi: 10.1016/j.ebiom.2025.105835.
2
Genome-wide scanning for genetic markers associated with anti-malarial drugs sensitivity of Plasmodium falciparum isolates from the China-Myanmar border region.对中国-缅甸边境地区恶性疟原虫分离株抗疟药物敏感性相关遗传标记进行全基因组扫描。
Malar J. 2025 Mar 12;24(1):78. doi: 10.1186/s12936-025-05319-4.
3
susceptibility to antimalarial drugs and polymorphisms in drug resistance genes of African , 2016-2023: a genotype-phenotype association study.

本文引用的文献

1
Delayed parasite clearance after treatment with dihydroartemisinin-piperaquine in Plasmodium falciparum malaria patients in central Vietnam.越南中部恶性疟原虫疟疾患者接受双氢青蒿素-哌喹治疗后寄生虫清除延迟。
Antimicrob Agents Chemother. 2014 Dec;58(12):7049-55. doi: 10.1128/AAC.02746-14. Epub 2014 Sep 15.
2
Dihydroartemisinin-piperaquine failure in Cambodia.双氢青蒿素-哌喹在柬埔寨治疗失败
N Engl J Med. 2014 Jul 31;371(5):484-5. doi: 10.1056/NEJMc1403007.
3
Randomized comparison of the efficacies and tolerabilities of three artemisinin-based combination treatments for children with acute Plasmodium falciparum malaria in the Democratic Republic of the Congo.
2016 - 2023年非洲人群对抗疟药物的敏感性及耐药基因多态性:一项基因型-表型关联研究
medRxiv. 2024 Jul 19:2024.07.17.24310448. doi: 10.1101/2024.07.17.24310448.
4
Prevalence of Mutations in the Gene and Association with Ex Vivo Susceptibility to Common Quinoline Drugs against .该基因中突变的发生率及其与针对……的常见喹啉类药物体外敏感性的关联。
Pharmaceutics. 2021 Aug 17;13(8):1273. doi: 10.3390/pharmaceutics13081273.
5
Ex-vivo Sensitivity of Plasmodium falciparum to Common Anti-malarial Drugs: The Case of Kéniéroba, a Malaria Endemic Village in Mali.疟原虫对常用抗疟药物的体外敏感性:以马里疟疾流行村庄肯涅罗巴为例。
Drugs R D. 2020 Sep;20(3):249-255. doi: 10.1007/s40268-020-00313-4.
6
Prevalence of mutations in the Plasmodium falciparum chloroquine resistance transporter, PfCRT, and association with ex vivo susceptibility to common anti-malarial drugs against African Plasmodium falciparum isolates.恶性疟原虫氯喹耐药转运蛋白(PfCRT)基因突变的流行情况及其与非洲恶性疟原虫分离株体外常见抗疟药物敏感性的关系。
Malar J. 2020 Jun 5;19(1):201. doi: 10.1186/s12936-020-03281-x.
7
Low polymorphisms in pfact, pfugt and pfcarl genes in African Plasmodium falciparum isolates and absence of association with susceptibility to common anti-malarial drugs.非洲恶性疟原虫分离株中 pfact、pfugt 和 pfcarl 基因的低多态性与常见抗疟药物敏感性无关。
Malar J. 2019 Aug 28;18(1):293. doi: 10.1186/s12936-019-2919-3.
8
Baseline and Molecular Responses of Plasmodium falciparum Isolates to Piperaquine before Implementation of Dihydroartemisinin-Piperaquine in Senegal.塞内加尔实施双氢青蒿素-哌喹之前恶性疟原虫分离株的基线和分子反应对哌喹的反应
Antimicrob Agents Chemother. 2019 Apr 25;63(5). doi: 10.1128/AAC.02445-18. Print 2019 May.
9
Susceptibility of Plasmodium falciparum to artemisinins and Plasmodium vivax to chloroquine in Phuoc Chien Commune, Ninh Thuan Province, south-central Vietnam.越南中南部宁顺省福川乡恶性疟原虫对青蒿素类药物的敏感性和间日疟原虫对氯喹的敏感性。
Malar J. 2019 Jan 17;18(1):10. doi: 10.1186/s12936-019-2640-2.
10
Malaria, tuberculosis and HIV: what's new? Contribution of the Institut Hospitalo-Universitaire Méditerranée Infection in updated data.疟疾、结核病与艾滋病:有哪些新情况?地中海感染大学医院研究所对最新数据的贡献。
New Microbes New Infect. 2018 Jul 4;26:S23-S30. doi: 10.1016/j.nmni.2018.06.003. eCollection 2018 Nov.
在刚果民主共和国对三种青蒿素联合疗法治疗儿童急性恶性疟原虫疟疾的疗效和耐受性进行随机比较。
Antimicrob Agents Chemother. 2014 Sep;58(9):5528-36. doi: 10.1128/AAC.02682-14. Epub 2014 Jul 7.
4
Ex vivo anti-malarial drugs sensitivity profile of Plasmodium falciparum field isolates from Burkina Faso five years after the national policy change.国家政策变更五年后布基纳法索恶性疟原虫现场分离株的体外抗疟药物敏感性概况
Malar J. 2014 May 31;13:207. doi: 10.1186/1475-2875-13-207.
5
Longitudinal outcomes in a cohort of Ugandan children randomized to artemether-lumefantrine versus dihydroartemisinin-piperaquine for the treatment of malaria.乌干达儿童接受青蒿琥酯-咯萘啶或双氢青蒿素-哌喹治疗疟疾的随机对照队列研究的纵向结局。
Clin Infect Dis. 2014 Aug 15;59(4):509-16. doi: 10.1093/cid/ciu353. Epub 2014 May 13.
6
Monitoring the efficacy and safety of three artemisinin based-combinations therapies in Senegal: results from two years surveillance.监测三种青蒿素类复方疗法在塞内加尔的疗效和安全性:两年监测结果。
BMC Infect Dis. 2013 Dec 20;13:598. doi: 10.1186/1471-2334-13-598.
7
A SYBR Green 1-based in vitro test of susceptibility of Ghanaian Plasmodium falciparum clinical isolates to a panel of anti-malarial drugs.一种基于 SYBR Green 1 的体外试验,用于检测加纳疟原虫临床分离株对一组抗疟药物的敏感性。
Malar J. 2013 Dec 17;12:450. doi: 10.1186/1475-2875-12-450.
8
Efficacy and safety of dihydroartemisinin-piperaquine for treatment of Plasmodium vivax malaria in endemic countries: meta-analysis of randomized controlled studies.双氢青蒿素-哌喹治疗疟疾流行国家间日疟的疗效与安全性:随机对照研究的荟萃分析
PLoS One. 2013 Dec 3;8(12):e78819. doi: 10.1371/journal.pone.0078819. eCollection 2013.
9
In vitro piperaquine susceptibility is not associated with the Plasmodium falciparum chloroquine resistance transporter gene.体外吡喹酮敏感性与恶性疟原虫氯喹耐药转运蛋白基因无关。
Malar J. 2013 Nov 25;12:431. doi: 10.1186/1475-2875-12-431.
10
PftetQ and pfmdt copy numbers as predictive molecular markers of decreased ex vivo doxycycline susceptibility in imported Plasmodium falciparum malaria.PftetQ 和 pfmdt 拷贝数可作为预测输入性恶性疟原虫疟疾患者体外强力霉素敏感性降低的分子标记物。
Malar J. 2013 Nov 14;12:414. doi: 10.1186/1475-2875-12-414.